Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study
HER2DX impacts clinical management in stage I-III HER2-positive BC by supporting treatment adjustments, enhancing physician confidence, maintaining pCR rates, and reducing health care costs.
Authors
- Pedro Jares (ORCID: https://orcid.org/0000-0002-8401-579X)
- T. Pascual
- Bárbara Adamo (ORCID: https://orcid.org/0000-0001-7129-8156)
- S. Marín-Liébana
- M.A. Rezqallah Aron (ORCID: https://orcid.org/0000-0001-9758-9402)
- F. Schettini
- Esther Carcelero
- Fara Brasó‐Maristany (ORCID: https://orcid.org/0000-0001-5440-9643)
- Juan Miguel Cejalvo (ORCID: https://orcid.org/0000-0002-8755-8626)
- Pablo Rivera
- Begoña Bermejo (ORCID: https://orcid.org/0000-0001-7773-5994)
- R Gómez-Bravo (ORCID: https://orcid.org/0009-0000-4090-4395)
- María Dolores Torregrosa (ORCID: https://orcid.org/0000-0002-1285-1131)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- Antonio Llombart‐Cussac (ORCID: https://orcid.org/0000-0003-4515-8293)
- Ana Santaballa (ORCID: https://orcid.org/0000-0001-7763-320X)
- Marta Tapia (ORCID: https://orcid.org/0000-0002-0266-1289)
- Cristina Hernándo (ORCID: https://orcid.org/0000-0002-6865-4196)
- E. Hernández-Illán
- Benjamín Walbaum (ORCID: https://orcid.org/0000-0003-2314-5360)
- C. Saura
- Ana Isabel Martínez-Puchol (ORCID: https://orcid.org/0000-0002-5158-0127)
- L. Paré
- A. Lluch
- Isabel García-Fructuoso (ORCID: https://orcid.org/0000-0002-7417-4703)
- Athanasios Pouptsis (ORCID: https://orcid.org/0000-0001-9469-6069)
- Esther Sanfeliu (ORCID: https://orcid.org/0000-0002-7974-3346)
- Vega Iranzo (ORCID: https://orcid.org/0000-0001-6183-5173)
- Santiago Escrivá-de-Romaní (ORCID: https://orcid.org/0000-0001-7816-7589)
- Núria Chic (ORCID: https://orcid.org/0000-0001-9736-6276)
- Patricia Villagrasa (ORCID: https://orcid.org/0000-0002-8662-3641)
- Iris Garrido‐Cano (ORCID: https://orcid.org/0000-0002-1211-473X)
- Mercedes Marín‐Aguilera (ORCID: https://orcid.org/0000-0002-2205-3459)
- Montserrat Muñoz-Mateu (ORCID: https://orcid.org/0000-0001-7772-1437)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Elia Seguí (ORCID: https://orcid.org/0000-0001-7770-9825)
- María Teresa Martínez (ORCID: https://orcid.org/0000-0003-1312-3555)
- Joan Anton Puig‐Butillé (ORCID: https://orcid.org/0000-0003-4345-9631)
- Octavio Burgués (ORCID: https://orcid.org/0000-0002-2471-5516)
- C. Tébar
- A. Magro
- Laura Palomar
- William Buckingham
- O. Martínez-Sáez
- B. Conte
Institutions
- Universitat de València (ES)
- Peter MacCallum Cancer Centre (AU)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital de La Ribera (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Center for Cancer and Blood Disorders (US)
- Hospital Quirónsalud Barcelona (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Arnau de Vilanova (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital General Universitario De Valencia (ES)
- Hospital de Sagunto (ES)
- Oryzon Genomics (Spain) (ES)
- Hospital Comarcal de Inca (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100123
- Citations
- 9
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 9.41
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Albert Einstein Cancer Center
- Les Laboratories Pierre Fabre
- Veracyte
- Seagen
- Fundación Científica Asociación Española Contra el Cáncer
- Eisai
- Instituto de Salud Carlos III
- Daiichi Sankyo Europe